Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Foteini Theodorakakou, Maria Roussou, Maria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis
{"title":"Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma","authors":"Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Foteini Theodorakakou, Maria Roussou, Maria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis","doi":"10.1002/jha2.889","DOIUrl":null,"url":null,"abstract":"<p>Background: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.</p><p>Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.</p><p>Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival. In a subset of patients with available samples at the time of disease progression, there was a trend for decreasing sBCMA values.</p><p>Conclusion: Sequential evaluation of sBCMA in prospective studies will determine the value of incorporating sBCMA measurement in clinical practice.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756978/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.889","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value.
Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay.
Results: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival. In a subset of patients with available samples at the time of disease progression, there was a trend for decreasing sBCMA values.
Conclusion: Sequential evaluation of sBCMA in prospective studies will determine the value of incorporating sBCMA measurement in clinical practice.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
